Muhammet A Kaplan1, Ulku Y Arslan2, Abdurrahman Işıkdogan1, Faysal Dane3, Berna Oksuzoglu2, Mevlude Inanc4, Tulay Akman5, Mehmet Kucukoner1, Havva Y Cinkir2, Rashad Rzazade3, Metin Ozkan4, Ugur Yilmaz5, Ibrahim V Bayoglu6, Yusuf Gunaydin7, Meltem Baykara8, Dogan Yazilitas9, Erdem Cubukcu10, Ali Suner11, Ugur Ersoy12, Mehmet Bilici13, Ozan Yazici14, Kerim Cayır13, Umut Demirci15, Mukremin Uysal16. 1. Dicle University School of Medicine, Department of Medical Oncology, Diyarbakir, Turkey. 2. Ankara Oncology Training and Research Hospital-2, Department of Medical Oncology, Ankara, Turkey. 3. Marmara University School of Medicine, Department of Medical Oncology, Istanbul, Turkey. 4. Erciyes University School of Medicine, Department of Medical Oncology, Kayseri, Turkey. 5. Dokuz Eylul University School of Medicine, Department of Medical Oncology, Izmir, Turkey. 6. I·zmir Ataturk Training and Research Hospital, Department of Medical Oncology, Izmir, Turkey. 7. Gazi University School of Medicine, Department of Medical Oncology, Ankara, Turkey. 8. Sakarya Training and Research Hospital, Department of Medical Oncology, Sakarya, Turkey. 9. Konya Training and Research Hospital, Department of Medical Oncology, Konya, Turkey. 10. Uludag University School of Medicine, Department of Medical Oncology, Bursa, Turkey. 11. Gaziantep University School of Medicine, Department of Medical Oncology, Gaziantep, Turkey. 12. Dıs¸kapı Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey. 13. Atatürk University School of Medicine, Department of Medical Oncology, Erzurum, Turkey. 14. Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey. 15. Ataturk Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey. 16. Afyon Kocatepe University School of Medicine, Department of Medical Oncology, Afyon, Turkey.
Abstract
PURPOSE: The aim of the study was to investigate the association between the molecular subtypes and patterns of relapse in breast cancer patients who had undergone curative surgery. METHODS: We retrospectively evaluated 1,350 breast cancer patients with relapses after curative surgery between 1998 and 2012 from referral centers in Turkey. Patients were divided into 4 biological subtypes according to immunohistochemistry and grade: triple negative, HER2 overexpressing, luminal A and luminal B. RESULTS: The percentages of patients with luminal A, luminal B, HER2-overexpressing, and triple-negative breast cancer were 32.9% (n = 444), 34.9% (n = 471), 12.0% (n = 162), and 20.2% (n = 273), respectively. The distribution of metastases differed among the subgroups: bone (66.2% and 53.9% in luminal A and B vs. 38.9% in HER2-overexpressing and 45.1% in triple negative, p < 0.001), liver (40.1% in HER2-overexpressing vs. 24.5% in luminal A, 33.5% in luminal B, and 27.5% in triple negative, p < 0.001), lung (41.4% in triple negative and 35.2% in HER2-overexpressing vs. 30.2% and 30.6% in luminal A and B, p = 0.008) and brain (25.3% in HER2-overexpressing and 23.1% in triple negative vs. 10.1% and 15.1% in luminal A and B, p < 0.001). CONCLUSIONS: Organ-specific metastasis may depend on the molecular subtype of breast cancer. Tailored strategies against distant metastasis concerning the molecular subtypes in breast cancer should be considered.
PURPOSE: The aim of the study was to investigate the association between the molecular subtypes and patterns of relapse in breast cancerpatients who had undergone curative surgery. METHODS: We retrospectively evaluated 1,350 breast cancerpatients with relapses after curative surgery between 1998 and 2012 from referral centers in Turkey. Patients were divided into 4 biological subtypes according to immunohistochemistry and grade: triple negative, HER2 overexpressing, luminal A and luminal B. RESULTS: The percentages of patients with luminal A, luminal B, HER2-overexpressing, and triple-negative breast cancer were 32.9% (n = 444), 34.9% (n = 471), 12.0% (n = 162), and 20.2% (n = 273), respectively. The distribution of metastases differed among the subgroups: bone (66.2% and 53.9% in luminal A and B vs. 38.9% in HER2-overexpressing and 45.1% in triple negative, p < 0.001), liver (40.1% in HER2-overexpressing vs. 24.5% in luminal A, 33.5% in luminal B, and 27.5% in triple negative, p < 0.001), lung (41.4% in triple negative and 35.2% in HER2-overexpressing vs. 30.2% and 30.6% in luminal A and B, p = 0.008) and brain (25.3% in HER2-overexpressing and 23.1% in triple negative vs. 10.1% and 15.1% in luminal A and B, p < 0.001). CONCLUSIONS: Organ-specific metastasis may depend on the molecular subtype of breast cancer. Tailored strategies against distant metastasis concerning the molecular subtypes in breast cancer should be considered.
Entities:
Keywords:
Breast cancer; Molecular subtype; Relapse pattern
Authors: Marcel Smid; Yixin Wang; Jan G M Klijn; Anieta M Sieuwerts; Yi Zhang; David Atkins; John W M Martens; John A Foekens Journal: J Clin Oncol Date: 2006-04-24 Impact factor: 44.544
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Martine Deckers; Maarten van Dinther; Jeroen Buijs; Ivo Que; Clemens Löwik; Gabri van der Pluijm; Peter ten Dijke Journal: Cancer Res Date: 2006-02-15 Impact factor: 12.701
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: Harri Sihto; Johan Lundin; Mikael Lundin; Tiina Lehtimäki; Ari Ristimäki; Kaija Holli; Liisa Sailas; Vesa Kataja; Taina Turpeenniemi-Hujanen; Jorma Isola; Päivi Heikkilä; Heikki Joensuu Journal: Breast Cancer Res Date: 2011-09-13 Impact factor: 6.466
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Amélie Darlix; Gaia Griguolo; Simon Thezenas; Eva Kantelhardt; Christoph Thomssen; Maria Vittoria Dieci; Federica Miglietta; PierFranco Conte; Antoine Laurent Braccini; Jean Marc Ferrero; Caroline Bailleux; William Jacot; Valentina Guarneri Journal: J Neurooncol Date: 2018-02-27 Impact factor: 4.130
Authors: Antonio Martínez-Aranda; Vanessa Hernández; Ferran Moreno; Núria Baixeras; Daniel Cuadras; Ander Urruticoechea; Miguel Gil-Gil; Noemí Vidal; Xavier Andreu; Miquel A Seguí; Rosa Ballester; Eva Castella; Angels Sierra Journal: Front Oncol Date: 2017-12-01 Impact factor: 6.244
Authors: José Manuel Sánchez-Villalobos; Alfredo Serna-Berna; Juan Salinas-Ramos; Pedro Pablo Escolar-Pérez; Emma Martínez-Alonso; Daniel G Achel; Miguel Alcaraz Journal: Colomb Med (Cali) Date: 2021-06-09